Clinical operations

Mitochondrial Replacement in IVF and the Evidence for Live Birth

What mitochondrial donation studies show, how to interpret fertility claims, and why IVF outcomes need age-specific live-birth rates and long-term follow-up.

By Lampgen Clinical Research

An IVF laboratory workstation sits beside the headline “Count every IVF cycle,” with live births per cycle started and long-term follow-up highlighted.
AI-generated editorial illustration of an embryology workstation.

4 min read · estimated

Sources
Per cycle startedPer embryo transfer
The denominator determines which IVF cycles a reported success rate includes.

What the source reported

Mitochondrial replacement has early clinical evidence for reducing the risk of passing on certain serious mitochondrial DNA diseases. Whether it improves live-birth odds for patients with age-related infertility remains unproven. A November 2, 2026, STAT investigation described how a cross-border fertility market has developed around that second claim. One patient told STAT she paid more than $30,000 for care arranged abroad. [1]

In pronuclear transfer, an embryology team moves the intended parents’ nuclear genetic material into a fertilized donor egg whose nuclear genetic material has been removed. The donor egg supplies most of the resulting embryo’s mitochondrial DNA. The procedure carries over the chromosome complement of the intended parents, including any chromosome abnormalities present in that material. [2]

In a 2025 UK case series, 22 women underwent a sperm injection procedure for pronuclear transfer. Researchers reported eight infants born, including twins, and one pregnancy still ongoing at the time of publication. The clinical follow-up report described all eight children as healthy at birth. Three infants had detectable levels of the maternal mitochondrial variant ranging from 5% to 16% in blood. One child later developed a heart rhythm problem and elevated blood lipids that responded to treatment. The small cohort and early follow-up leave uncommon and later outcomes uncertain. [2, 3]

STAT’s November 3 follow-up described evidence that small amounts of maternal mitochondrial DNA carried over at transfer can increase over time. Some of the data reviewed by STAT remain unpublished. Tracking the children over time matters because a measurement at birth represents one tissue at one point in development. [2, 11]

Fertility research has asked a different question. A 2023 pilot studied maternal spindle transfer, a related technique performed before fertilization, in 25 couples with repeated IVF failure. The study focused on women under 40 and reported six children born across 28 cycles. It had a single-arm design and provides feasibility evidence for that selected population. ESHRE recommends against using mitochondrial replacement to improve egg quality. [4, 5]

STAT reported that a fertility facilitator advertised a pregnancy success rate above 50% and declined to supply age-specific rates. The facilitator told STAT that partner clinics perform the procedures and that patients should be informed of uncertainty and alternatives. In the UK, the HFEA licenses mitochondrial donation for serious inherited mitochondrial disease and approves cases individually. In the U.S., federal appropriations provisions bar FDA from accepting applications for human clinical research using MRT. FDA establishment registration and approval for a clinical use are separate regulatory determinations. [1, 6–8]

What this means for trial teams

Start with every initiated cycle. A live-birth rate per embryo transfer covers the subset that reached transfer. A rate per cycle started also captures cycles that ended because retrieval was canceled, no eggs were retrieved or no embryo was available to transfer. The CDC presents rates by different denominators for patients using their own eggs. Studies of fertility interventions should report the number of cycles started, the number resulting in at least one live birth and the time allowed for follow-up. Publish age-specific results and account for repeat cycles and missing outcomes. [9]

Design the comparison around the patients being counseled. A study of MRT for age-related infertility needs a prespecified comparison with standard IVF in a relevant patient population. Age at retrieval, prior cycles and reason for treatment matter to interpretation. A prospectively defined endpoint and clear reporting of uncertainty would make it possible to judge whether the procedure adds enough benefit to justify its burden.

Plan follow-up before patients travel. A cross-border protocol should name who tracks pregnancy outcomes, who receives urgent reports and who coordinates follow-up for children after birth. A consent discussion should explain the evidence for the proposed use, the total expected costs, the alternatives and who will take over care when the patient returns home. A records transfer and local follow-up plan reduce the burden on patients who would otherwise have to coordinate care themselves.

Account for who can complete follow-up. Time away from work, repeat travel and caregiving can affect whose outcomes are recorded. Plan local or remote follow-up where feasible and report how often outcomes are missing, by site and patient group where sample sizes allow. [10]

Consistent reporting could give patients and referring clinicians a way to compare programs before a trip is booked. It would also help investigators see which age groups and clinical indications warrant further study.

Sources

  1. STAT • Megan Molteni’s investigation of mitochondrial replacement and fertility tourism, November 2, 2026
  2. Hyslop et al. • Mitochondrial donation and preimplantation genetic testing for mtDNA disease, NEJM, 2025
  3. McFarland et al. • Clinical follow-up after mitochondrial donation, NEJM, 2025
  4. Costa-Borges et al. • Maternal spindle transfer pilot study, Fertility and Sterility, 2023
  5. ESHRE • Good practice recommendations on add-ons in reproductive medicine, 2023
  6. HFEA • Mitochondrial donation eligibility and licensing
  7. FDA • U.S. restrictions on clinical research using mitochondrial replacement techniques
  8. 21 CFR § 1271.27 • FDA establishment registration
  9. CDC • How to interpret assisted reproductive technology success rates
  10. Lampgen Clinical Insights • Clinical trial participation burden and patient access
  11. STAT • Follow-up investigation on safety and mitochondrial DNA carryover, November 3, 2026

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?